Lantheus Lists Two ASCO 2026 Oncology Imaging Presentations

Key Takeaways

• Lantheus announced two ASCO 2026 oncology imaging presentations covering osteosarcoma and early-stage prostate cancer.
• One item is a Monday, June 1 poster in the Sarcoma session, poster 376b, tied to a phase 1/2 LNTH-2403 study in relapsed or refractory osteosarcoma.
• A second item is a publication-only genitourinary cancer abstract, number e17126, focused on real-world piflufolastat F 18 use and imaging-associated treatment patterns in early-stage prostate cancer.

Lantheus said it will feature data at the 2026 ASCO Annual Meeting in Chicago, Illinois, from May 29 to June 2, 2026. The company identified two oncology-related abstracts: an early-phase osteosarcoma poster and a publication-only prostate cancer analysis. Together, the presentations span radiopharmaceutical development and a real-world imaging use study in early-stage disease.

The sarcoma presentation is scheduled for Monday, June 1, in the Sarcoma session as poster 376b. Its title describes a phase 1/2, multi-center, open-label study of LNTH-2403, a LRRC15-targeted lutetium-177-labeled monoclonal antibody, in patients with relapsed or refractory osteosarcoma. The stated aims are safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity. Noah Federman of the UCLA Jonsson Comprehensive Cancer Center and UCLA David Geffen School of Medicine in Los Angeles is the listed presenter.

The second item appears as publication only within Genitourinary Cancer—Prostate, Testicular, and Penile, with abstract number e17126. Its title centers on real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer. Emma Billmyer of The Analysis Group in Boston is listed as first author. The abstract focuses on imaging use and treatment patterns in early-stage disease.